Adjuvant endocrine therapy impact on bone health in premenopausal women with hormone receptor-positive breast cancer: Results of a case series

2021 ◽  
Author(s):  
Diana Lambrinoc ◽  
Duşceac Roxana ◽  
Alexandru Morea ◽  
Poiană Cătălina
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Bone Health ◽  
Hormone Receptor ◽  
Case Series ◽  
Premenopausal Women ◽  
Adjuvant Endocrine Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Endocrine Therapy in Premenopausal Hormone Receptor–Positive Breast Cancer

2016 ◽  
Vol 12 (11) ◽  
pp. 1148-1156 ◽  
Author(s):  
Amye J. Tevaarwerk ◽  
Kari B. Wisinski ◽  
Ruth M. O’Regan
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Systemic Therapy ◽  
Hormone Receptor ◽  
Randomized Trials ◽  
Early Stage ◽  
Premenopausal Women ◽  
Breast Cancers ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Systemic therapy for premenopausal women with hormone receptor–positive breast cancer has evolved in the last 5 years, but critical questions remain. Recent randomized trials have demonstrated a benefit for the addition of ovarian suppression to endocrine therapy in patients with breast cancers considered to be at high risk for recurrence, whereas those with lower-risk cancers seem to have a favorable outcome with tamoxifen alone. Two large randomized trials have demonstrated a benefit for extending adjuvant tamoxifen beyond 5 years. Currently the choice of systemic therapy is selected empirically but molecular profiling may, in the near future, provide a more conclusive means of selecting an endocrine therapeutic approach for premenopausal patients. Given that a significant subset of hormone receptor–positive cancers are intrinsically resistant to endocrine agents, as well as the finding that inhibiting cyclin-dependent kinases 4 and 6 and mammalian target of rapamycin appears to potentially reverse this resistance in patients with metastatic disease, evaluation of these agents in the early-stage setting is ongoing.

scholarly journals Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer

The Breast ◽  
2013 ◽  
Vol 22 ◽  
pp. S171-S175 ◽  
Author(s):  
Kathrin Strasser-Weippl ◽  
Tanja Badovinac-Crnjevic ◽  
Lei Fan ◽  
Paul E. Goss
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Adjuvant Endocrine Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document